(Q31975873)

5 July 2017

1 reference

title

Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians (English)

1 reference

5 July 2017

main subject

anti-retroviral agent

0 references

1 reference

Stein DS

1

1 reference

5 July 2017

Moore KH

series ordinal

2

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

5 July 2017

1 reference

5 July 2017

volume

21

1 reference

5 July 2017

issue

1

1 reference

5 July 2017

page(s)

11-34

1 reference

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

RNA-dependent DNA polymerase in virions of RNA tumour viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of Rous Sarcoma Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

DNA polymerases of eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Effects of 2?,3?-dideoxynucleosides on mammalian cells and viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Rapid evolution of RNA genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Enzymatic phosphorylation and pyrophosphorylation of 2',3'-dideoxyadenosine-5'-monophosphate, a key metabolite in the pathway for activation of the anti-HIV (human immunodeficiency virus) agent 2',3'-dideoxyinosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Lamivudine (3TC) phosphorylation and drug interactions in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

In vivo antagonism with zidovudine plus stavudine combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Deoxycytidine kinase from human leukemic spleen: preparation and characteristics of homogeneous enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

A novel human phosphotransferase highly specific for adenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Deoxycytidine and 2',3'-dideoxycytidine metabolism in human monocyte-derived macrophages. A study of both anabolic and catabolic pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Molecular targets for AIDS therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Regulation of thymidine kinase synthesis in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

In vitro toxicity and metabolism of 2',3'-dideoxycytidine, an inhibitor of human immunodeficiency virus infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Amplification and expression of genes associated with multidrug resistance in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Isolation and expression of a complementary DNA that confers multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

The biochemistry of P-glycoprotein-mediated multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Human immunodeficiency virus I-induced expression of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Nucleoside transport in isolated human and rhesus choroid plexus tissue slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Intracellular metabolism of 3'-azido-3'-deoxythymidine (AZT): a nuclear magnetic resonance study on T-lymphoblastoid cell lines with different resistance to AZT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Zidovudine induces the expression of cellular resistance affecting its antiviral activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Ribavirin antagonizes the effect of azidothymidine on HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2'-beta-fluoro-2',3'-dideoxyadenosine in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Mechanisms of Action of Mycophenolic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Clinical pharmacokinetics of zidovudine. An overview of current data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Clinical pharmacokinetics of nucleoside antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

A pilot study of low-dose zidovudine in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Further study of the mechanism underlying the cellular resistance to AZT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Mitochondrial toxicity of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.11.34439

10.1592/PHCO.21.1.11.34439

21 January 2018

Identifiers

DOI

1 reference

5 July 2017

1 reference